Thymofox

Thymofox is a private preclinical biotechnology company developing targeted, orally available medicines intended to regenerate the thymus and restore adaptive immune function. The company is focused on immune reconstitution in aging and immunocompromised patients, with a strategy centered on thymic regeneration rather than conventional anti-infective or oncology therapeutics. Thymofox appears to be a venture-created company associated with Apollo Health Ventures and is led by Chris Shepard, with scientific founding input reported from Jarrod Dudakov and Marcel van den Brink. Publicly available information suggests the company remains early stage, with limited disclosed pipeline details and no named clinical-stage assets.